Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 4, 2023, Novavax, Inc. (Nasdaq: NVAX) announced its participation in the World Vaccine Congress (WVC) and the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company will showcase data on its COVID-19 prototype vaccine as a booster and its COVID-Influenza Combination (CIC) vaccine. Key presentations include insights on vaccine hesitancy and safety surveillance, scheduled from April 3 to 6 in Washington, DC, and April 15 to 18 in Copenhagen, Denmark. Novavax is also a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards in two categories, with winners announced on April 4.
Novavax (Nasdaq: NVAX), a leader in protein-based vaccines, announced its participation in the TD Cowen's 43rd Annual Health Care Conference on March 8, 2023, from 9:50 – 10:20 a.m. EST. The conference will take place at the Boston Marriott Copley Place. John Trizzino, Chief Commercial Officer, will represent the company during a fireside chat moderated by Georgi Yordanov, an Equity Research Analyst in Biotechnology. A replay of the session will be accessible on Novavax's website for 90 days post-conference.